Atom Bioscience has revealed positive results from its China Phase IIa clinical trial of ABP-671, its URAT1 inhibitor for chronic gout. The randomised, double-blind, placebo-controlled trial enrolled 54 patients with gout or across six cohorts, with seven randomised to ABP-671 and two to placebo per cohort. “The results from our Phase IIa clinical trial in […]
